




Ten years later, this very idea became one of the biggest biotech exits in Europe: The US pharmaceutical company Gilead acquired the Munich biotech startup Tubulis for up to five billion US dollars. Munich Startup has spoken with its partners.(Photo: AI-generated)

read more ↓